Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Chen Qiyu: In the future, Fosun Pharma should be a development model of "technological innovation driven" and "service closed-loop driven"
Category:
Trade info
Author:
Source:
Add time:2017-07-20 15:42
Summary:On July 7, at the inauguration ceremony of Fosun Pharma's technology innovation incubation platform, Chen Qiyu, Co-President of Fosun Group and Chairman of Fosun Pharma, gave a wonderful keynote speech.
On July 7, at the inauguration ceremony of Fosun Pharma's technology innovation incubation platform, Chen Qiyu, Co-President of Fosun Group and Chairman of Fosun Pharma, gave a wonderful keynote speech.
In the keynote speech, student Chen talked about the future development model of Fosun Pharma, the development trend of China's pharmaceutical industry, and also talked about the step-by-step innovation and development of Fosun Pharma in the field of research and development, as well as the expectation of cooperation with Professor Xu Tian this time. .
The editor exclusively shared, about why we need to set up a technology innovation incubation platform, and listen to what Student Chen said at the press conference...
The following is the speech of student Chen
"The future of Fosun Pharma should be a two-wheel-drive development model driven by technological innovation and closed-loop service."
Dear Professor Xu Tian, good afternoon, friends from the media. We have been looking forward to the establishment of this incubator platform for a long time. After more than 20 years of growth and development, Fosun Pharma has paid more and more attention to technological innovation, especially in the past decade. The future of Fosun Pharma should be a two-wheel drive development model of "technological innovation driven" and "service closed-loop driven". The first driving force is in the field of pharmaceutical and device R&D and manufacturing, which is more driven by technological innovation, continuous improvement, and creation of innovative products; the second driving force is mainly in medical services, and the joint venture Sinopharm Holdings in the distribution and retail The closed-loop creation of service formats. In my opinion, these two wheels are the most important and core driving points for Fosun Pharma's future development in the pharmaceutical and medical fields.
"Achieving breakthroughs in R&D and innovation is far from enough in China alone. Our company must have global capabilities."
Judging from the development of China in recent years, especially the pharmaceutical industry and the pharmaceutical industry are making continuous progress. This progress is not only the expansion and growth of the industry and the growth of profitability, but more importantly, the continuous improvement of our R&D technology level. Recalling the PCR diagnostic reagents that Fosun made in the early days of its business, and then after we entered the entire pharmaceutical industry, we started to explore from scratch; until 2002, we acquired the Chongqing Medical Engineering Institute, hoping to use this platform to strengthen the research and development of medicine, to Later, we realized that pharmaceutical innovation is a global matter. The best technology and the best team are in the United States. To achieve breakthroughs in R&D innovation, it is not enough in China. Our company must have global capabilities; therefore After 2007 and 2008, we continued to explore the grafting of American medical research resources, and founded Fuhong Henlius and Fuchuang.
Today, we are in the forefront of monoclonal antibody research and development. In the face of future development, we have carried out a series of VC layouts on the existing basis. We hope that through VC layout, Fosun will create a more in-depth and more cutting-edge strategic outpost to feel the driving force of future technological development. To know in which areas this motivation will occur and promote changes in various industries. At the end of last year, Fosun Pharma was able to develop and establish contacts in the industry through such a layout. Recently, we have established joint ventures or joint ventures in China with Intuitive Surgical and Kite Pharma. These two partners can be said to be "the crown jewels" in their respective industries. I think this is very important for us in driving innovation. A milestone.
"Professor Xu Tian is a role model, role model and idol for the students of Fudan Department of Genetics"
The intersection between us and Professor Xu Tian didn't just start more than a year ago. When I was studying genetics at Fudan University, Professor Xu Tian was already a role model, role model and idol for genetics students. During the exchange and learning process with Professor Xu Tian in the past year, we have learned a lot about some of the cutting-edge medical high-tech fields that we thought of in the past but are still exploring, seeing but still trying, learning but still specializing. Science and technology, and these cutting-edge technologies have actually been explored and tried in the United States for a certain period of time. Just like the Internet industry today, China and the United States are actually the two largest countries in the world with successful entrepreneurship. Based on this, I believe that in the field of life science innovation, in addition to the United States, China should also be a very important driving force in the world. China's main advantage lies in the overall market size and our population base. Of course, we are also well aware that if we continue to develop, we have the ability to do the market, but how we will occupy the heights of the Chinese market in the future and how we will go to the global market in the future will not do well by simply relying on capital docking and simple marketing. Not enough, more sustained and explosive growth comes from the technological level.
Prof. Xu Tian’s achievements are not only in academics, but also contributed a lot to the practice of industrialization. The operation of the incubator of the Rosberg Institute in the United States is also very successful. It is also the beginning of such a cooperation between our two parties today. It is an opportunity to combine with Professor Xu Tian’s long-term industry experience. Fosun Pharma is not only an investor, but also a platform for combining industry and technology. The industry of Chinese companies can incubate and master a group of very cutting-edge and global technology and technology in the world’s life sciences and medical fields, and incubate a wave of talents who can realize the growth vision of Fosun Pharma. It also contributes to China's medical business and global medical business.
Thanks again to Professor Xu Tian for his trust in Fosun Pharma, and I also look forward to the cooperation between us to achieve very good and successful results. Thanks again to the media friends for their long-term support, thank you everyone!
